AstraZeneca Announces Next Phase for Heart Drug Brilinta

March 14, 2015 9:44 PM

15 0

AstraZeneca recently conducted a study to investigate the efficacy and safety of its new anti-clotting drug, which they call Brilinta.

Brigham and Women’s Hospital and Harvard Medical School cardiologist Dr. Marc Sabatine led the study. His team observed the results of the more than 21,000 in 31 countries who had taken the drug; all of whom had survived a heart attack within the last three years.

Read more

To category page